{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:59:26Z","timestamp":1764997166994,"version":"3.37.3"},"reference-count":31,"publisher":"Wiley","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TTUHSC Clinical Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p><jats:italic>Purpose<\/jats:italic>. Highly resistant Gram-negative bacterial infections are associated with high mortality. Increasing resistance to standard therapy illustrates the need for alternatives when treating resistant organisms, especially extended-spectrum beta-lactamase- (ESBL-) producing <jats:italic>Enterobacteriaceae<\/jats:italic>. <jats:italic>Methods<\/jats:italic>. A retrospective chart review at a community hospital was performed. Patients who developed ESBL-producing infections were included. Patients less than eighteen years old, who were pregnant, or who were incarcerated were excluded. The primary outcome was hospital mortality. The secondary outcomes included intensive care unit (ICU) mortality, ICU length of stay, and hospital length of stay. <jats:italic>Results<\/jats:italic>. 113 patients with ESBL-producing infections met the criteria for review. Hospital mortality: carbapenem (16.6%), cefepime (0%), and levofloxacin (15.3%) (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><mml:mrow><mml:mi>p<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.253<\/mml:mn><\/mml:mrow><\/mml:math>). ICU mortality: carbapenem (4.5%), cefepime, (0%), and levofloxacin (3.7%) (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><mml:mrow><mml:mi>p<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.616<\/mml:mn><\/mml:mrow><\/mml:math>). Mean ICU and hospital length of stay: carbapenem (9.8\u2009\u00b1\u200916, 12.1\u2009\u00b1\u20091 days), cefepime (7.8\u2009\u00b1\u20096, 11.1\u2009\u00b1\u200910.5 days), and levofloxacin (5.4\u2009\u00b1\u20094.1, 11.1\u2009\u00b1\u200910.4 days) (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\"><mml:mrow><mml:mi>p<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.805<\/mml:mn><mml:mo>,<\/mml:mo><mml:mn>0.685<\/mml:mn><\/mml:mrow><\/mml:math>). No predictors were clearly found between the source of infection and mortality. <jats:italic>Conclusion<\/jats:italic>. Cefepime or levofloxacin can be a potential alternative agent for infections with ESBL-producing <jats:italic>Enterobacteriaceae<\/jats:italic>, and larger clinical trials investigating these outcomes are warranted.<\/jats:p>","DOI":"10.1155\/2018\/3747521","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T18:31:41Z","timestamp":1518114701000},"page":"1-6","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacteriaceae<\/i> Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems"],"prefix":"10.1155","volume":"2018","author":[{"given":"Kristy J.","family":"Walker","sequence":"first","affiliation":[{"name":"Hendrick Medical Center, 1900 Pine St., Abilene, TX 79601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-2125","authenticated-orcid":true,"given":"Young R.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, 1718 Pine St., Abilene, TX 79601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Klar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, 1718 Pine St., Abilene, TX 79601, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.2165\/11533040-000000000-00000"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1086\/500936"},{"issue":"4","key":"4","first-page":"354","volume":"73","year":"2009","journal-title":"Journal of Hospital Infection"},{"issue":"2","key":"5","first-page":"155","volume":"3","year":"2009","journal-title":"International Journal of Health Sciences"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx099"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01487-06"},{"issue":"1","key":"8","first-page":"82","volume":"47","year":"2004","journal-title":"Indian Journal of Pathology and Microbiology"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01856.x"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.39.6.2206-2212.2001"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1086\/313719"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1128\/aac.06365-11"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1086\/324742"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00508-09"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1154538"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.5.1643-1646.2003"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.11.3442-3447.2003"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.09.004"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.05419-11"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt450"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis916"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00580-08"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2015.08.012"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.37"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1128\/aac.38.3.547"},{"year":"2012","key":"27"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2502-x"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1086\/500663"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.48.12.4574-4581.2004"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.03.013"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx113"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.023"}],"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/2018\/3747521.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/2018\/3747521.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/2018\/3747521.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T18:31:43Z","timestamp":1518114703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cjidmm\/2018\/3747521\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":31,"alternative-id":["3747521","3747521"],"URL":"https:\/\/doi.org\/10.1155\/2018\/3747521","relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"type":"print","value":"1712-9532"},{"type":"electronic","value":"1918-1493"}],"subject":[],"published":{"date-parts":[[2018]]}}}